Cochrane group: Roche's refusal of access to Tamiflu data leaves questions unanswered
This article was originally published in Scrip
Executive Summary
Researchers from the Cochrane Collaboration have highlighted Roche's refusal to provide full access to all its data on the anti-influenza drug Tamiflu (oseltamivir), which the group says "leaves critical questions about how well the drug works unresolved".